Synapse Loss as Therapeutic Target in MS

As we age, the number of synapses present in the human brain starts to decline, but in neurodegenerative diseases this occurs at a much more rapid rate. In MS it has been shown that there is a reduction in synaptic density, which is a potential area to target for treatment. Here is the latest research on synapse loss as a therapeutic target in MS.

May 13, 2020
Review

Could non-invasive brain-stimulation prevent neuronal degeneration upon ion channel re-distribution and ion accumulation after demyelination?

Neural Regeneration Research
Friederike Pfeiffer, Alia Benali
July 1, 2020
Review

Dopamine: an immune transmitter

Neural Regeneration Research
Sarah Thomas BroomeAlessandro Castorina
May 14, 2020

CYBB/NOX2 in conventional DCs controls T cell encephalitogenicity during neuroinflammation

Autophagy
Christian W KellerJan D Lünemann
June 25, 2020

Molecular signature of slowly expanding lesions in progressive multiple sclerosis

Brain : a Journal of Neurology
Katharina JäckleWolfgang Brück
May 23, 2020

Effect of sildenafil on neuroinflammation and synaptic plasticity pathways in experimental autoimmune encephalomyelitis

International Immunopharmacology
Shyrlene Meiry da Rocha AraújoChristina Alves Peixoto
July 2, 2020
Open Access

Synaptic loss in the multiple sclerosis spinal cord

Annals of Neurology
N PetrovaK Schmierer
May 28, 2020
Review

Impact of Age on Multiple Sclerosis Disease Activity and Progression

Current Neurology and Neuroscience Reports
Burcu Zeydan, Orhun H Kantarci
June 5, 2020
Review

Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis

Clinical Reviews in Allergy & Immunology
Insha Zahoor, Shailendra Giri
May 14, 2020
Open Access

Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions

Brain : a Journal of Neurology
Nina L FransenInge Huitinga
June 9, 2020
Review

Glia in neurodegeneration: Drivers of disease or along for the ride?

Neurobiology of Disease
Amy J Gleichman, S Thomas Carmichael
May 9, 2020
Open Access

Personal Autonomy as Quality of Life Predictor for Multiple Sclerosis Patients

Journal of Clinical Medicine
Rodica PadureanuAdina Turcu-Stiolica
May 13, 2020

A Multi-Ligand Imaging Study Exploring GABAergic Receptor Expression and Inflammation in Multiple Sclerosis

Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging
Yeona KangSusan A Gauthier
June 19, 2020
Preprint
Open Access

GLP-1R agonist NLY01 reduces retinal inflammation, astrocyte reactivity, and retinal ganglion cell death secondary to ocular hypertension.

BioRxiv : the Preprint Server for Biology
J. K. SterlingQi N Cui

Sign up to follow this feed and discover related papers.

Related Feeds

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

Acute Disseminated Encephalomyelitis

Acute disseminated encephalomyelitis (ADEM) is a rare inflammatory demyelinating disease of the central nervous system. Discover the latest research on acute disseminated encephalomyelitis here.

© 2020 Meta ULC. All rights reserved
/feed-previews/synapse-loss-as-therapeutic-target-in/371c8616-9261-4314-b041-1af69c1703ff